TMC435 with peginterferon/ribavirin may treat chronic HCV

  • April 30, 2012

Protease inhibitor TMC435 administered with peginterferon/ribavirin may be an effective treatment for patients with chronic hepatitis C who had experienced little or no response to prior peginterferon/ribavirin treatment, according to results presented at the International Liver Congress in Barcelona, Spain.

In a phase 2b, double blind study, researchers randomly assigned 462 patients into seven groups receiving the following once-daily treatments:

  •              100 mg TMC435 with peginterferon/ribavirin (P/R) for 12 weeks
  •               100 mg TMC435 with P/R for 24 weeks
  •               100 mg TMC435 with P/R for 48 weeks
  •               150 mg TMC435 with P/R for 12 weeks
  •               150 mg TMC435 with P/R for 24 weeks
  •               150 mg TMC435 with P/R for 48 weeks
  •               P/R with a placebo for 48 weeks

All participants had chronic HCV) genotype 1 and had previously experienced relapse or null or partial response to one or more courses of P/R therapy. Evaluated factors included sustained virologic response (SVR) and the occurrence of adverse events.

SVR had occurred 24 weeks after treatment in 61% to 80% of participants among the six groups that received the drug, compared with 23% of patients in the control group (P<.001). Rapid response after four weeks was experienced by 53% to 68% of participants within individual groups, compared with 2% of placebo patients.

Viral relapse occurred in 6% to 18% of participants within the drug groups, compared with 44% in the control group. Discontinuation of treatment because of a lack of response or viral breakthrough occurred in 9% to 17% of patients in the drug groups, compared with 53% of the control group. Adverse events experienced by patients were similar across all groups. A mild, asymptomatic bilirubin increase was observed among patients receiving the treatment, with no difference in severity between the two dosages.

“Following treatment with TMC435 plus P/R, patients who failed previous P/R treatment exhibited significantly higher SVR24 rates compared with placebo, including difficult-to-treat prior null-responders with cirrhosis,” the researchers wrote. “TMC435 was well-tolerated in this population.”

For more information:

Zeuzem S. Abstract #2. Presented at: The International Liver Congress, April 18-22, Barcelona, Spain.

Comments

Healio is intended for health care provider use and all comments will be posted at the discretion of the editors. We reserve the right not to post any comments with unsolicited information about medical devices or other products. At no time will Healio be used for medical advice to patients.